Tag Archives: Keytruda’s

With ‘evolved’ treatment landscape, Merck pulls Keytruda’s FDA nod in third-line stomach cancer

Two months after a key FDA panel voted down Merck’s conditional nod for Keytruda as a third-line treatment for certain stomach cancer patients, the company says it’s pulling the plug on the indication.  Following consultation with the FDA, Merck on Thursday said it will voluntarily withdraw its U.S. accelerated approval for Keytruda as a third-line… Read More »

Merck treads on Sanofi, Regeneron’s turf with Keytruda’s latest skin cancer OK

It’s a feeling Sanofi and Regeneron’s immuno-oncology rivals know all too well: Merck & Co.’s Keytruda just moved into a market you had cornered. Now, the pair is about to get its first taste of that particular brand of competition. The FDA Wednesday approved Keytruda in recurrent or metastatic cutaneous squamous cell carcinoma that can’t be… Read More »